3rd Quarter - Report

GLENMARK PHARMACEUTICALS USA for GLENMARK PHARMACEUTICALS USA

Firm
Client
Income
—
Expenses
$131,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA User Fees, HR 749, Lower Drug Costs Through Competition Act, CREATES Act (HR 2212 and S 974), Generic CPI penalty.

Foreign entity interest: Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.

LobbyistCovered position, as disclosed
GRANT ERDEL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2212 (115th), H.R. 749 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.